Polaris Group

Equities

6550

KYG7171A1085

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 06/03/2026			5-day change	1st Jan Change
30.60 ^TWD	+0.99%		-8.11%	-1.61%

12-26	Polaris Group Announces Management Changes, Effective December 26, 2025	CI
12-26	Polaris Group Announces Chief Executive Officer Changes, Effective December 26, 2025	CI

Polaris Group Announces Resignation of Steve J.P. Hsu as Chief Executive Officer, Effective December 24, 2025

Published on 12/16/2025 at 09:33 am GMT

S&P Capital IQ

POLARIS GROUP

+0.99%

Polaris Group announced that Steve J.P. Hsu, CEO, has resigned from his position. The effective date of the resignation is December 24, 2025. Following the effectiveness of the CEO's resignation, the Company will proceed to identify a successor and make the required announcement in accordance with applicable laws and regulations.

Latest news about Polaris Group

12-26	Polaris Group Announces Management Changes, Effective December 26, 2025	CI
12-26	Polaris Group Announces Chief Executive Officer Changes, Effective December 26, 2025	CI
12-25	Polaris Group announced that it expects to receive TWD 3.2 billion in funding	CI
12-17	Polaris Group's CEO Resigns	MT
12-16	Polaris Group Announces Resignation of Steve J.P. Hsu as Chief Executive Officer, Effective December 24, 2025	CI
12-16	Polaris Group Names New Chairman; Shares Rally 10%	MT
12-15	Polaris Group Announces Management Changes, Effective December 24, 2025	CI
11-12	Polaris Group Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
01/09/25	Polaris Group Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
19/08/25	Polaris Cancer Drug Candidate Enters FDA Substantive Review	MT
21/07/25	Polaris Unit Grants Drug Distribution Rights to Bioprofarma Bago	MT
11/06/25	Polaris Group Completes Submission of US FDA Application for Rare Lung Cancer Drug	MT
10/06/25	Polaris Group Completes Rolling Submission of Biologic License Application for ADI-PEG 20 with FDA to Treat Malignant Pleural Mesothelioma	CI
14/05/25	Polaris Group Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25/04/25	Polaris Group Announces Changes in the Board of Directors on Behalf of Key Subsidiary Designerx Pharmaceuticals, Inc	CI

Chart Polaris Group

Duration

Period

6550: Dynamic Chart

Company Profile

The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Companyâ€™s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.

Employees

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data